You're describing a chemical compound with a rather complex name! It's actually better known by its shorter name: **Tivozanib**.
**Tivozanib** is a small-molecule tyrosine kinase inhibitor. Tyrosine kinases are enzymes that play a crucial role in cell signaling and growth. Tivozanib specifically inhibits the activity of several tyrosine kinases, including:
* **VEGFR-1 (Flt-1)**: This is a major receptor for vascular endothelial growth factor (VEGF), a protein that stimulates blood vessel formation.
* **VEGFR-2 (KDR)**: Another key receptor for VEGF, also crucial for blood vessel growth.
* **VEGFR-3 (Flt-4)**: Important in lymphatic vessel development.
* **FGFR1-3 (Fibroblast Growth Factor Receptor 1-3)**: These receptors are involved in various processes like cell growth, differentiation, and tissue repair.
**Why Tivozanib is Important for Research:**
* **Cancer Treatment:** By inhibiting angiogenesis (the formation of new blood vessels), Tivozanib helps prevent tumors from getting the nutrients and oxygen they need to grow. It's being investigated for the treatment of various cancers, including:
* **Renal Cell Carcinoma (RCC)**: Tivozanib is approved for treating advanced RCC.
* **Colorectal Cancer:** It is being studied for the treatment of metastatic colorectal cancer.
* **Other Cancers:** Research is ongoing to evaluate its potential in other solid tumors.
* **Other Potential Applications:** Tivozanib's ability to block blood vessel formation is also being explored for its potential in treating:
* **Diabetic Retinopathy:** A complication of diabetes that can lead to vision loss.
* **Age-Related Macular Degeneration (AMD)**: A leading cause of vision loss in older adults.
**Key Points:**
* Tivozanib is a powerful inhibitor of several tyrosine kinases involved in blood vessel growth and other cellular processes.
* It's being studied for its potential to treat various cancers and other diseases.
* Its mechanism of action (blocking angiogenesis) makes it a promising agent in the fight against cancer and other conditions.
**Note:** Tivozanib is a prescription medication, and its use should be discussed with a qualified healthcare professional.
| ID Source | ID |
|---|---|
| PubMed CID | 178086 |
| SCHEMBL ID | 1230394 |
| MeSH ID | M0256737 |
| Synonym |
|---|
| fandofloxacin hydrochloride |
| 164150-85-0 |
| dw-116 |
| 1-(5-fluoro-2-pyridyl)-6-fluoro-7-(4-methyl-1- piperazinyl)-1,4-dihydro-4-oxoquinolone-3-carboxylic acid hydrochloride |
| fandofloxacino |
| fandofloxacin hcl |
| DTXSID1043918 |
| SCHEMBL1230394 |
| 1-(5-fluoro-2-pyridyl)-6-fluoro-7-(4-methyl-1-piperazinyl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid hydrochloride |
| 6-fluoro-1-(5-fluoropyridin-2-yl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid;hydrochloride |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The plasma concentration of DW116 declined monoexponentially with a half-life range of 16-22 hr." | ( Pharmacokinetics and urinary excretion of DW116, a new fluoroquinolone antibacterial agent, in humans as a phase I study. Choi, MH; Chung, BC; Jung, BH, 2000) | 0.31 |
| " The T(1/2)abs, T(1/2)beta, AUC, Tmax and Cmax in the maternal plasma were approximately 6 min, 13." | ( Transplacental pharmacokinetics of the new fluoroquinolone DW-116 in pregnant rats. Bae, CS; Chung, MK; Han, J; Kim, JC; Kim, SH; Park, SC; Shin, HC; Yun, HI, 2003) | 0.32 |
| Excerpt | Reference | Relevance |
|---|---|---|
| ", the percent bioavailability was 90." | ( Pharmacokinetics of 1-(5-fluoro-2-pyridyl)-6-fluoro-7-(4-methyl-1- piperazinyl)-1,4-dihydro-4-oxoquinolone-3-carboxylic acid hydrochloride (DW-116), a new quinolone antibiotic in rats. Chung, SJ; Lee, MH; Shim, CK; Yu, IL, 1997) | 0.3 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Its pharmacokinetics indicate that once-daily dosing may be possible." | ( Safety, tolerability and pharmacokinetics of the new long-acting quinolone DW-116 after single and multiple dosing in healthy subjects. Choi, MS; Chung, YH; Dilger, C; Lee, CW; Lee, DK; Meyerhoff, C; Pabst, G; Reh, C; Ryu, JM; Yoon, SJ, 1998) | 0.3 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (50.00) | 18.2507 |
| 2000's | 7 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.37) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (13.33%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (86.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||